311308/canadian-government-invests-75m-more-in-aspect-biosystems
AMS X

Canadian Government Invests $75M More in Aspect Biosystems

Formnext
RAPID

Share this Article

Canadian bioprinting startup Aspect Biosystems has received a $72.75 million investment from Canada and the province of British Columbia. This supports earlier investments amounting to $200 million in Aspect’s technology and a partnership with Novo Nordisk.

“This significant investment from the Governments of Canada and B.C. sends a strong signal of support for building and integrating the capabilities needed to discover, develop, and clinically manufacture new medicines for people with serious diseases. This is a major step forward on our bold mission to pioneer an entirely new category of regenerative medicine and build an enduring and globally leading biotech that is delivering sustainable, life-changing impact to patients at home and around the world,” said Aspect Biosystems CEO Tamer Mohamed.

“Today’s investment in Aspect Biosystems strengthens Canada’s biotech sector, enhancing innovation and leadership in health care. It accelerates our transition from ideas to globally competitive products, while also bolstering our response to health emergencies, attracting international investments and creating high-quality jobs for Canadians. British Columbia’s impressive talent pool further fuels our innovation and leadership in the next generation of medicines,” stated François-Philippe Champagne, Minister of Innovation, Science and Industry.

“B.C. is home to the fastest growing life sciences sector in Canada and continues to get noticed on the global stage for the incredible work being done here. Helping B.C. based life sciences and biomanufacturing companies like Aspect anchor and grow in our province is enhancing health care outcomes for British Columbians and creating hundreds of new, high-paying, highly skilled jobs for people,” said Brenda Bailey, British Columbia Minister of Jobs, Economic Development and Innovation.

It’s rare for governments to invest directly in tech startups, and rarer still for multiple parts of the same country to contribute funds. Could this approach be more efficient than just giving grants? It might allow governments to profit from entrepreneurial success, enabling further investment in local startups. However, it could also make government bodies more like VCs, potentially fostering a short-term focus and reducing long-term technological innovation. Additionally, it might make them more likely to follow trends rather than fund truly unique ventures. This is a puzzling trend to watch.

Why does Aspect need so much money? Aspect is an implantable tissue company, but instead of betting on finding one tissue that works or bringing a single tissue to market, they are taking a smarter approach. The company is building a technology platform that allows others to use its complete bioprinting infrastructure to bring their drugs to market. This strategy is brilliant because it offloads the $1 billion to $3 billion cost of drug development to the drug companies. Instead of saying, “buy our printers,” Aspect offers drug firms the ability to use and rely on their technology from inception to commercialization.

This approach seems much more robust and future-proof than single systems. It also makes working with Aspect much stickier, generating more revenue from clients throughout the engagement’s lifetime. Rather than taking a company-sized bet on one drug, the firm aims to become the connective tissue for tissue discovery. French company Poietis has a similar setup. Aspect calls this approach the “full-stack tissue therapeutic platform.”

Rather than aiming for a single win with one drug, the company is integrating its technology with that of big pharma companies. It may not directly cure diabetes, but it will enable partners like Novo Nordisk to develop many drugs. If this infrastructure approach succeeds, the exit will be impressive enough for all investors. It’s worth noting that the Novo Nordisk partnership alone is said to be worth $2.6 billion. Everyone always talks about selling picks and shovels in a gold rush; invest now in Aspect’s shovel factory.



Share this Article


Recent News

Bambu Wants to Run Circles Around You

Formnext 2026: Four Booths Not to Miss!



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

Axtra3D Rolls Out New Software, Wash and Cure Systems at Formnext 2026

Axtra3D has made a number of strides forward of late, introducing new software workflow tools, a new FR material together with Arkema, and new washing and curing stations. The company...

3D Printing News Briefs, November 14, 2026: Chuck Hull, Tungsten Carbide, Movie Costume, & More

In this weekend’s 3D Printing News Briefs, we are of course starting off with some Formnext news ahead of the big event this coming week. Then we’ll move on to...

Two Farsoon Machine Launches & How Chinese AM OEMs Are Shifting Focus

In posts last month about Eplus3D and how it’s scaling production for the AI infrastructure market, I focused on how the Chinese additive manufacturing (AM) landscape looks poised to intensify...

3D Printing News Briefs, November 11, 2026: Financing, Distributor, Kickstarter, & More

We’re starting off with exciting AMUG news in today’s 3D Printing News Briefs, as Neil Hopkinson was selected for the 2027 Innovators Award. Then we’ll move on to business, with...